Search the Newsreel

Corteva, Inc. $CTVA Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Corteva, Inc. (NYSE:CTVA) by 7.0% in the first quarter of 2026, selling 27,060 shares. Despite this, Corteva reported strong second-quarter adjusted EPS of $2.30, exceeding analyst estimates, and raised its fiscal 2026 EPS outlook. Analysts …

Corteva forecasts $4.1B-$4.3B operating EBITDA and targets October 1 separation date

Earnings Call Insights: Corteva (CTVA) Q2 2026 MANAGEMENT VIEW * "The headline for this quarter is straightforward. We are delivering strong results. We are raising our full year outlook, and we are on track to complete our separation on October 1." (CEO & Director …

Corteva Inc Stock (CTVA) Moved Down by 10.51% on Jul 31: What Signal Does It Send?

Corteva Inc. (CTVA) stock dropped over 10% after missing second-quarter revenue and earnings estimates and lowering full-year EBITDA guidance. This decline is attributed to reduced crop protection demand, lower commodity prices impacting farmer spending, and distributor destocking due to high interest rates. Analysts have …

Corteva (CTVA) Lifts 2026 Outlook As Split Plans Stay On Track

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Corteva (NYSE:CTVA) reported strong first half 2026 results. The company raised its full year 2026 outlook based on current business performance. Corteva confirmed it is …

Corteva Q2 Earnings Call Highlights

Key Points Interested in Corteva, Inc.? Here are five stocks we like better. Corteva raised its 2026 outlook after strong first-half results, now targeting operating EBITDA of $4.1 billion–$4.3 billion and operating EPS of $3.60–$3.80. First-half sales rose 4% to $11.3 billion, while EBITDA …

Corteva's Seeds Spinoff Will Leave a Pure-Play Crop Protection Company

Corteva, an agriculture company formed from DowDuPont, plans to spin off its seeds business, Vylor, in late 2026. This move will transform the remaining Corteva entity into a pure-play crop protection company. Currently, seeds generate approximately 66% of Corteva's profits, with crop protection accounting …

Are You Looking for a Top Momentum Pick? Why Corteva, Inc. (CTVA) is a Great Choice

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

Corteva sets separation date for company’s crop protection, seed businesses

Corteva Inc. has announced that the separation of its agricultural products division into independent crop protection and seed businesses will take place on December 1, 2026. This move follows a strategic review initiated in 2025 aimed at unlocking shareholder value. Both new companies will …

Earnings call transcript: Corteva Q2 2026 beats EPS, stock drops 10%

Corteva (CTVA) reported mixed Q2 2026 results, beating EPS expectations with $2.30 per share but missing revenue forecasts at $6.38 billion. The company's stock subsequently dropped 10.02% to $80.39. Despite ongoing pricing pressure in crop protection, particularly in Brazil, Corteva raised its full-year 2026 …

Corteva, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:CTVA) 2026-07-31

Corteva, Inc. published a slide deck in conjunction with their Q2 2026 earnings call, where they reported an EPS of $2.30, beating estimates by $0.07. However, the company's revenue of $6.38 billion, a 1.19% year-over-year decrease, missed expectations by $219.12 million. This article provides …

Corteva Q2 Earnings Beat Estimates, Sales Miss, '26 Outlook Raised

Corteva, Inc. (CTVA) reported mixed Q2 2026 results, with earnings beating estimates but sales missing. The company saw a 1% decline in revenues year-over-year to $6.38 billion, but operating earnings per share increased 4.5% to $2.30. Despite competitive pricing in Crop Protection, strong Seed …

Corteva, Inc. $CTVA Shares Bought by Empowered Funds LLC

Empowered Funds LLC increased its stake in Corteva, Inc. (NYSE:CTVA) by 36.3% during the first quarter, now owning 125,758 shares valued at $10.53 million. This comes amidst other institutional investors also adjusting their positions in the company. Corteva recently reported strong second-quarter earnings, beating …

Amundi Acquires 528,373 Shares of Corteva, Inc. $CTVA

Amundi has significantly increased its stake in Corteva, Inc. (NYSE:CTVA) by acquiring an additional 528,373 shares, bringing its total holdings to over 2.9 million shares. This move reflects continued institutional investment in Corteva, despite a slight dip in the stock's opening price and a …

Corteva warnt trotz Anhebung der Gewinnprognose für das Gesamtjahr vor stagnierendem Gewinn im zweiten Halbjahr

Corteva (CTVA) Raised 2026 Guidance And Kept Its October Split On Track

Escorts Kubota shares gain 2.06% to trade at Rs 3,075.80

Corteva, Inc. (NYSE:CTVA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Corteva, Inc. (NYSE:CTVA) has received a "Moderate Buy" consensus recommendation from twenty-two brokerages, with an average 12-month price target of $90.19. The company recently reported mixed quarterly results, beating EPS estimates but missing on revenue, and issued fiscal 2026 EPS guidance of $3.60-$3.80. Corteva …

Corcept Therapeutics Number of Employees 2026 | Employee Count & Headcount Data

Corcept Therapeutics (NASDAQ: CORT) had approximately 753 total employees worldwide as of March 2026, marking a 125.5% growth from 2023. The company is actively hiring, despite a 22.5% decline in active job postings from 2025 to 2026. Most of its workforce is concentrated in …

CORCEPT THERAPEUTICS INC 2Q 2026: Revenue $256.15M, EPS $0.36— 10-Q Summary

CORCEPT THERAPEUTICS INC reported strong second-quarter 2026 results, with product revenue reaching $256.15M, net income of $42.14M, and diluted EPS of $0.36, all showing significant year-over-year growth. This performance was driven by the commercial launch of Lifyorli for platinum-resistant ovarian cancer and continued growth …

Corteva, Inc. (CTVA) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2026, Corteva, Inc. (CTVA) reported revenue of $6.38 billion, down 1.2% over the same period last year. EPS came in at $2.30, compared to $2.20 in the year-ago quarter. The reported revenue represents a surprise of -3.66% over the …

Corteva, Inc. (CTVA) Q2 Earnings Beat Estimates

Corteva, Inc. (CTVA) came out with quarterly earnings of $2.3 per share, beating the Zacks Consensus Estimate of $2.24 per share. This compares to earnings of $2.2 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Corteva raises full-year profit forecast

Corteva, Inc. (CTVA) has raised its full-year adjusted profit forecast due to strong demand across key crop markets, specifically citing the acreage shift from corn to soybeans. The company now anticipates full-year earnings per share to be between $3.60 and $3.80, up from an …

Corteva (NYSE: CTVA) lifts 2026 guidance and advances Vylor spin-off plan

Corteva, Inc. reported strong Q2 and H1 2026 results, leading the company to raise its full-year 2026 guidance for non-GAAP Operating EBITDA to $4.1-$4.3 billion and Operating EPS to $3.60-$3.80 per share. The company also confirmed it is on track to complete the planned …

Corteva, Inc.: Q2 Earnings Snapshot

Corteva, Inc. (CTVA) reported a strong second quarter, with a profit of $1.16 billion, or $1.73 per share. Adjusted earnings of $2.30 per share surpassed Wall Street expectations, though revenue of $6.38 billion fell short of forecasts. The agriculture company anticipates full-year earnings between …

Corteva to Bring Enclosa Herbicide to U.S. Soybean Farmers

Corteva is introducing Enclosa herbicide to U.S. soybean farmers, a new product designed for exceptional weed control with up to four weeks of residual activity. It combines encapsulated acetochlor (Group 15) and cloransulam (Group 2), offering multiple modes of action to manage weeds and …

Corteva Delivers Strong 1H 2026, Raises FY 2026 Outlook, On-Track for October 1 Separation

Seed 1H results reflect continued value capture on latest in-demand germplasm and trait technologies, including licensing growth Crop Protection 1H demand for new products and focus on operational excellence helped offset competitive pricing dynamics Full-year 2026 guidance3 increased to reflect strong first half performance, …

Corcept Therapeutics (CORT) affiliate files to sell 40,000 shares after option exercise

An affiliate of Corcept Therapeutics (CORT), Atabak Mokari, has filed a notice to sell 40,000 shares of common stock through Stifel Nicolaus & Company on or about July 30, 2026, on Nasdaq. These shares relate to stock option exercises from February 13, 2023. This …

Corteva earnings up next amid plans to split into two firms

Corteva Inc. is set to announce its second-quarter earnings, with analysts anticipating a strong performance driven by the peak planting season. The company is also progressing with its plan to separate into two publicly-traded entities by the end of 2026, making this earnings report …

CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised

Corcept Therapeutics CORT reported second-quarter 2026 earnings of 36 cents per share, beating the Zacks Consensus Estimate of a loss of 4 cents. In the year-ago quarter, the company had reported earnings of 29 cents. Second-quarter revenues rose nearly 32% year over year to …

S&P 500 Futures Rise in Premarket Trading; Corcept Therapeutics, FormFactor Lead

S&P 500 futures showed an increase in premarket trading, with Corcept Therapeutics Inc. (CORT) and FormFactor Inc. (FORM) leading the gains. Corcept Therapeutics was up 21.3% and FormFactor was up 16.4% ahead of the market open. The article highlights these two companies as top …

Corcept: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for Corcept. Due to the brevity of the original content, no further details about the earnings are available.

Janus Henderson Group PLC Sells 354,050 Shares of Corteva, Inc. $CTVA

Janus Henderson Group PLC reduced its stake in Corteva, Inc. by 4.7% in the first quarter, selling 354,050 shares, but still holds over 7.2 million shares valued at $607.2 million. Other institutional investors like William B. Walkup & Associates Inc. and Wilkerson Advisory Group …

Corcept Therapeutics stock hits 52-week high at 112.0 USD

Corcept Therapeutics' stock hit a new 52-week high of $112.00, driven by strong market sentiment and exceptional year-to-date gains of 167%. Despite appearing overvalued by InvestingPro analysis, the company reported robust Q2 2026 revenues of $256 million, a 32% year-over-year increase, and raised its …

Corcept Therapeutics (NASDAQ:CORT) Surges 21% After Q2 Earnings Beat and Raised Guidance

Corcept Therapeutics (NASDAQ:CORT) reported strong Q2 results, significantly surpassing analyst expectations due to robust performance from its new oncology drug, Lifyorli, and its Cushing’s syndrome franchise. The company also raised its full-year 2026 revenue guidance, leading to a 21% surge in its stock in …

16,499 Shares in Corcept Therapeutics Incorporated $CORT Acquired by Entropy Technologies LP

Corteva raises full-year profit forecast, shares fall after revenue miss

Corteva, Inc. (CTVA) has raised its full-year adjusted profit forecast due to strong demand across key crop markets, specifically citing the acreage shift from corn to soybeans. The company now anticipates full-year earnings per share to be between $3.60 and $3.80, up from an …